Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support

This episode, titled ‘Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support,’ featured panelists discussing the following critical questions:

What is the clinical burden associated with extrapulmonary neuroendocrine carcinoma that is put on patients?

What are the best patient resources for those affected by extrapulmonary neuroendocrine carcinoma?

What is the role of the caregiver in patients with neuroendocrine carcinomas?

How should healthcare providers include patients and caregivers in shared decision-making?

Led by the moderator, the expert oncologists examined the profound physical burden that extrapulmonary neuroendocrine carcinoma (epNEC) places on patients, including rapid deterioration of performance status, organ dysfunction, bone involvement, bleeding, and significant weight loss, underscoring the urgency of initiating effective frontline therapy. William Oh, Aman Chauhan, Namrata Vijayvergia, and Sandy Kotiah emphasized the importance of treating patients holistically, addressing not only their disease but also their mental health, financial concerns, and overall quality of life through nurse navigators, social workers, and patient support resources. The panelists highlighted that caregivers — including spouses, family members, and loved ones — play a critical role in helping patients navigate their diagnosis and treatment, with data suggesting that strong support systems are associated with improved outcomes. They also stressed the value of meeting patients where they are in terms of their desired level of involvement, and incorporating both patients and caregivers into a shared decision-making framework throughout the treatment journey.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, ‘Current Treatments and Biomarker Testing in Extrapulmonary Neuroendocrine Carcinoma: Strengths, Limitations, and Clinical Relevance,’ panelists continue their discussion on extrapulmonary neuroendocrine carcinoma and highlight the current treatment landscape including platinum-based chemotherapy and immune checkpoint inhibitors, the strengths and limitations of existing therapies, and the biomarkers most clinically relevant for guiding treatment decisions.